Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative
Document Transition Report
Document Transition Report
Research, option and milestone expense.
Research, Option And Milestone Expense
Research, option and milestone expense
Money Market Funds [Member]
Money Market Funds [Member]
Cash, cash equivalents and investments, Amortized cost
Cash Cash Equivalents And Investments Amortized Cost Basis
Cash cash equivalents and investments amortized cost basis.
Geographical [Axis]
Geographical
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period
Share based compensation granted under plan vest period
Debt Securities, Available-for-Sale
Available for sale debt securities, Fair value
Debt Securities, Available-for-sale, Total
Other Liabilities, Noncurrent
Other non-current liabilities
Other Liabilities, Noncurrent, Total
Restricted Stock Units (RSUs) [Member]
Restricted Stock Units [Member]
Fair Value, Inputs, Level 1 [Member]
Level 1 [Member]
Prepaid research expenses, current.
Prepaid Research Expenses Current
Prepaid research expenses
Receivable Type [Axis]
Other Accruals [Member]
Schedule of Other Current Assets [Table Text Block]
Summary of Other Current Assets
Phantom Share Units (PSUs) [Member]
Revenue from Contract with Customer, Excluding Assessed Tax
Products, net
Revenue from Contract with Customer, Excluding Assessed Tax, Total
Product revenues, net
Prepaid Expense and Other Assets, Current [Abstract]
Reduction to right of use assets and lease liabilities
Reduction To Right Of Use Assets And Lease Liabilities
Reduction To Right Of Use Assets And Lease Liabilities
Disaggregation of Revenue [Table Text Block]
Summary of Product Revenues
Concentration Risk Type [Axis]
Concentration Risk Type
Sublicense payment.
Sublicense Payment
Sublicense payment
Contract with Customer, Liability, Current
Deferred revenue, current portion
Accrued Sponsored Research Agreements
Accrued Sponsored Research Agreements
Accrued sponsored research agreements
Share-Based Payment Arrangement, Cost by Plan [Table Text Block]
Summary of Stock-Based Compensation Expense by Grant Type Included within Consolidated Statements of Operations and Comprehensive Loss
Title of Individual [Domain]
Payment for option exercise.
Payment For Option Exercise
Payment for option exercise
Other Nonoperating Income
Other income (expense), net
Deposit Liabilities, Accrued Interest
Eliminated accrued interest
Operating Lease, Liability, Noncurrent
Lease liabilities, net of current portion
Manufacturing-related deposits and prepaid expense current.
Manufacturing Related Deposits And Prepaid Expense Current
Manufacturing-related deposits and prepaids
Cash deposits and money market funds.
Cash Deposits And Money Market Funds [Member]
Cash and Money Market Funds [Member]
Liabilities, Fair Value Disclosure
Total liabilities
Fair value at the beginning of the period
Fair value at the end of the period
Fair value at the beginning of the period
Liabilities, Fair Value Disclosure, Total
Debt Instrument, Unamortized Discount
Unamortized discount
Debt Instrument, Unamortized Discount, Total
Balance Sheet Location [Axis]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table]
Schedule Of Accounts Notes Loans And Financing Receivable [Table]
Assets, Current
Total current assets
Vesting [Domain]
Liabilities and Equity
Total liabilities and stockholders’ equity
Entity Address, State or Province
Entity Address, State or Province
Accrued clinical and preclinical costs current.
Accrued Clinical And Preclinical Costs Current
Accrued clinical and pre-clinical costs
Prepaid medical affairs expenses.
Prepaid Medical Affairs Expenses
Prepaid medical affairs expenses
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted Average Grant Date Fair Value, Stock options
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive loss
Inventory Disclosure [Text Block]
INVENTORY
Trading Symbol
Trading Symbol
Debt Instrument, Redemption, Period [Axis]
Common stock, shares issued
Common Stock, Shares, Issued
Common Stock, Shares, Issued, Total
Long-Term Debt, Maturity, Year Two
2025
Chargebacks.
Chargebacks [Member]
Chargebacks [Member]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Amortization of discounts premiums investments cash equivalent and short term investment.
Amortization Of Discounts Premiums Investments Cash Equivalent And Short Term Investment
Accretion of investment discount, net
Accretion of investment discount, net
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract]
Cash, cash equivalents and restricted cash:
Cash and Cash Equivalents [Member]
Cash and Cash Equivalents [Member]
Schedule of Long-Term Debt Instruments [Table]
Debt Instrument [Table]
Shares, Outstanding
Balance (in shares)
Balance (in shares)
Rebates.
Rebates [Member]
Rebates [Member]
Other Comprehensive Income (Loss), Net of Tax
Total other comprehensive income (loss)
Summary of change in reserves for discounts and allowances.
Summary Of Change In Reserves For Discounts And Allowances Table [Text Block]
Summary of Change in Reserves for Discounts and Allowances
Accounts receivable payment term.
Accounts Receivable Payment Term
Accounts receivable payment term
Increase decrease in accumulated deficit.
Increase Decrease In Accumulated Deficit
Decrease in accumulated deficit
Other Assets, Miscellaneous, Current
Other
Entity Address, City or Town
Entity Address, City or Town
Convertible debt and term loan and revolver and mortgage loans.
Convertible Debt And Term Loan And Revolver And Mortgage Loans [Member]
Convertible Debt, The Term Loan, The Revolver and The Mortgage Loans [Member]
2023 (July-December)
Long-Term Debt, Maturity, Remainder of Fiscal Year
Lessee, Operating Lease, Renewal Term
Leases, term of contract extend
Debt Disclosure [Text Block]
INDEBTEDNESS
Accounting standard update two thousand and sixteen to two thousand and eighteen.
Accounting Standard Update Two Thousand And Sixteen To Two Thousand And Eighteen [Member]
ASU 2020-06
Commitments and contingencies.
Commitments And Contingencies [Line Items]
Commitments And Contingencies [Line Items]
Customer two.
Customer Two [Member]
Customer Two [Member]
Chief Executive Officer [Member]
Chief Executive Officer
Additional Paid-in Capital [Member]
Additional Paid-In Capital [Member]
Non-US [Member]
Outside of U.S. [Member]
Liabilities, Current [Abstract]
Current liabilities:
2017 Capped Calls Partial Settlement [Member]
Two Thousand Seventeen Capped Calls Partial Settlement [Member]
Two Thousand Seventeen Capped Calls Partial Settlement [Member]
Assets, Current [Abstract]
Current assets:
Accounts Receivable, Allowance for Credit Loss, Current
Ending balance
Beginning balance
Total reserves
Counterparty Name [Axis]
Counterparty Name
Preferred Stock, Par or Stated Value Per Share
Preferred stock, par value
Statement of Stockholders' Equity [Abstract]
Bio Marin Pharmaceutical Incorporation.
Bio Marin Pharmaceutical Incorporation [Member]
BioMarin Pharmaceutical, Inc. [Member]
Lease liabilities terminated
Lease Liabilities Terminated
Lease liabilities terminated.
Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]
Summary of Fair Value of Level 3 Financial Liabilities
Collaboration Receivable.
Collaboration Receivable
Collaboration Receivable
Debt Instrument, Maturity Date
Debt instrument, maturity date
Cash and cash equivalents gross unrealized gain before tax.
Cash And Cash Equivalents Gross Unrealized Gain Before Tax
Cash and cash equivalents, Gross unrealized gains
Other Nonoperating Income and Expense [Text Block]
OTHER LOSS, NET
Aggregate long-term debt
Long-Term Debt
Net carrying value
Property, Plant and Equipment, Net
Property and equipment, net
Property, Plant and Equipment, Net, Total
Property, Plant and Equipment, Net, Beginning Balance
Property, Plant and Equipment, Net, Ending Balance
Available for sale debt securities current accumulated gross unrealized loss before tax.
Available For Sale Debt Securities Current Accumulated Gross Unrealized Loss Before Tax
Available for sale debt securities current, Gross unrealized losses
Investment Income, Interest
Interest income
Business Combination, Contingent Consideration, Liability
Contingent consideration
Contingent consideration
Business Combination, Contingent Consideration, Liability, Total
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Entity Central Index Key
Entity Central Index Key
Implemented fee
Amendment Implemented Fee
Restricted Cash, Noncurrent
Restricted cash in other assets
Assets, Fair Value Disclosure
Total assets
Fair value, at the beginning of the period
Fair value, at the end of the period
Assets, Fair Value Disclosure, Total
Net decrease in other assets
Increase (Decrease) in Other Operating Assets
Increase (Decrease) in Other Operating Assets, Total
Conversion of shares excluded from computation of diluted EPS
Conversion of shares excluded from computation of diluted EPS
Conversion of shares excluded from computation of diluted EPS
Preferred Stock, Shares Outstanding
Preferred stock, shares outstanding
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred Stock, Shares Outstanding, Ending Balance
Liabilities, Current
Total current liabilities
Entity Tax Identification Number
Entity Tax Identification Number
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Loss before income tax expense (benefit)
Inventory, Finished Goods, Net of Reserves
Finished goods
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Financial Instruments [Domain]
Financial Instruments
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]
Accumulated Other Comprehensive (Loss) Income [Member]
Schedule of Other Assets, Noncurrent [Table Text Block]
Summary of Other Non-current Assets
Increase (decrease) in additional paid in capital.
Increase Decrease In Additional Paid In Capital
Decrease in additional paid-in-capital
Stock Issued During Period, Value, Employee Stock Purchase Plan
Issuance of common stock under employee stock purchase plan
Prepaid commercial.
Prepaid Commercial
Prepaid commercial expenses
SummaryOfInventoryBalanceSheetClassificationTableTextBlock
SummaryOfInventoryBalanceSheetClassificationTableTextBlock
Summary Of Inventory Balance Sheet Classification
Lessee, Operating Leases [Text Block]
LEASES
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents [Abstract]
Geographical [Domain]
Geographical
Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer
Collaboration
Assets
Total assets
UNITED STATES
U.S. [Member]
Noncash or Part Noncash Acquisition, Fixed Assets Acquired
Intangible assets and property and equipment included in accounts payable and accrued expenses
Operating Lease, Right-of-Use Asset
Right of use assets
Accrued contract manufacturing expense current.
Accrued Contract Manufacturing Expense Current
Accrued contract manufacturing costs
Entity Registrant Name
Entity Registrant Name
Debt Issuance Costs, Net
Unamortized discount - debt issuance costs
Debt Issuance Costs, Net, Total
Lessee, Lease, Description [Line Items]
Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date.
Long Term Debt Maturities Repayments Of Principal After Year Four
2027
Retained Earnings (Accumulated Deficit)
Accumulated deficit
Retained Earnings (Accumulated Deficit), Ending Balance
Retained Earnings (Accumulated Deficit), Total
Retained Earnings (Accumulated Deficit), Beginning Balance
Supplemental Cash Flow Information [Abstract]
Supplemental disclosure of cash flow information:
Partial settlement of capped call
Partial settlement of capped call share options for 2024 Notes
Partial settlement of capped call share options for 2024 Notes
Partial settlement of capped call share options for 2024 Notes
Retained Earnings [Member]
Accumulated Deficit [Member]
Liabilities, Fair Value Adjustment
Fair value of contingent consideration liability
Two Thousand And Nineteen Term Loan Member
Two Thousand And Nineteen Term Loan [Member]
2019 Term Loan [Member]
Inventory, Raw Materials, Net of Reserves
Raw materials
Nationwide license agreement.
Nationwide License Agreement [Member]
Nationwide License Agreement [Member]
2022 Capped Call Transactions [Member]
2022 Capped Call Transactions [Member]
Cash cash equivalents and investments.
Cash Cash Equivalents And Investments
Cash, cash equivalents and investments, Fair value
Stock Issued During Period, Shares, Employee Stock Purchase Plans
Issuance of common stock under employee stock purchase plan, shares
Minimum [Member]
Minimum [Member]
Revenues
Total revenues
Revenues
Other Assets, Miscellaneous, Noncurrent
Other
Proceeds from Stock Options Exercised
Proceeds from exercise of stock options and purchase of stock under the Employee Stock Purchase Program
Significant Accounting Policies [Text Block]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Operating lease liability
Operating Lease, Liability, Total
Operating Lease, Liability
Share-Based Payment Arrangement, Tranche One [Member]
Unvested Tranche Member
US Government Agencies Debt Securities [Member]
Government and Government Agency Bonds [Member]
Equity Component [Domain]
Equity Component
Cash, Cash Equivalents and Investments [Table Text Block]
Summary of Company Cash, Cash Equivalents and Short-Term Investments
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Adjustments to reconcile net loss to cash flows from operating activities:
Remaining expense associated
Remaining expense associated in share
Remaining expense associated in share
Debt Disclosure [Abstract]
Share-Based Payment Arrangement, Plan Modification, Incremental Cost
Incremental compensation cost
Entity Current Reporting Status
Entity Current Reporting Status
Common Stock, Shares Authorized
Common stock, shares authorized
Research and Development Expense
Research and development expense
Research and Development Expense, Total
Cash and Cash Equivalents [Line Items]
Cash and Cash Equivalents [Line Items]
Debt Conversion, Converted Instrument, Amount
Common stock issued for exchange of 2024 Notes
Share-Based Payment Arrangement, Activity [Table Text Block]
Summary of Stock Awards Granted
Assets [Abstract]
Assets
Amortization of Intangible Assets
Amortization of in-licensed rights
Amortization of Intangible Assets, Total
Prompt pay.
Prompt Pay [Member]
Prompt Pay [Member]
Common stock, $0.0001 par value, 198,000,000 shares authorized; 93,273,541 and 87,950,117 issued and outstanding at June 30, 2023, and December 31, 2022, respectively
Common Stock, Value, Issued
Common Stock, Value, Issued, Total
Common Stock, Value, Issued, Beginning Balance
Common Stock, Value, Issued, Ending Balance
Gain from sale of intangible asset.
Gain From Sale Of Intangible Asset [Line Items]
Gain From Sale Of Intangible Asset [Line Items]
Other
Other Noncash Income (Expense)
Other
Other Noncash Income (Expense), Total
Collateralized Letter of Credit Cash Deposit
Collateralized Letter of Credit Cash Deposit
Cash and cash equivalents gross unrealized loss before tax.
Cash And Cash Equivalents Gross Unrealized Loss Before Tax
Cash and cash equivalents, Gross unrealized losses
Accrued Liabilities, Current
Accrued expenses
Total accrued expenses
Current Fiscal Year End Date
Current Fiscal Year End Date
Share-Based Payment Arrangement, Noncash Expense
Stock-based compensation
Share-based Payment Arrangement, Noncash Expense, Total
Operating Income (Loss)
Operating loss
Payments credits reserves for discounts and allowances.
Payments Credits Reserves For Discounts And Allowances
Payments/credits
Accrued milestone and license costs
Accrued milestone expense current.
Accrued Milestone Expense Current
Income Tax Expense (Benefit)
Income Tax Expense (Benefit), Total
Income tax expense (benefit)
Revenue, Product and Service Benchmark [Member]
Product Revenues [Member]
Research and Development Expense [Member]
Research and Development Expense [Member]
Research and Development [Member]
2026
Long-Term Debt, Maturity, Year Four
Contractual Obligation, Fiscal Year Maturity [Table Text Block]
Summary of Aggregate Non-Cancelable Contractual Obligations Arising from Manufacturing Obligations
Sales milestone payment recorded as an in-license right
Milestone payment
Finite-Lived License Agreements, Gross
Debt Conversion Costs
Debt Conversion Costs
Debt conversion costs for 2024 Notes
Debt conversion costs for 2024 Notes
Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale
Maturity and sale of available-for-sale securities
Proceeds from Sale and Maturity of Debt Securities, Available-for-sale, Total
Other, net
Other Nonrecurring (Income) Expense
Other Nonrecurring (Income) Expense, Total
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
ACCRUED EXPENSES
Concentration Risk, Percentage
Concentration of credit risk percentage
Share-Based Payment Arrangement, Expense
Total stock-based compensation expense
Stock-based compensation expense
installments date
Installments Date of implemented fee
Weighted average maturity period of available for sale securities.
Weighted Average Maturity Period Of Available For Sale Securities
Weighted average maturity period of available-for-sale securities
Finite-Lived Intangible Assets, Net
Intangible assets, net
Finite-Lived Intangible Assets, Net, Total
Finite-Lived Intangible Assets, Net, Beginning Balance
Finite-Lived Intangible Assets, Net, Ending Balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total
Grants, Stock options
Stock options granted to CEO
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Other comprehensive income (loss):
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]
Reconciliation of cash, cash equivalents and restricted cash:
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Debt Instrument, Face Amount
Debt instrument, face amount
Total payments
Principal amount
Cumulative Effect, Period of Adoption, Adjustment [Member]
Cumulative Effect of Accounting Change [Member]
Other Nonoperating Income (Expense)
Other, net
Other income (expense), net
Other income (expense), net
Significant Accounting Policies [Policy Text Block]
Significant Accounting Policies [Policy Text Block]
Significant Accounting Policies
Long-Term Debt, Type [Domain]
Contractual Obligation, to be Paid, Year Four
2027
Columbus Ohio
Columbus Ohio [Member]
Commitments and Contingencies Disclosure [Abstract]
Other Assets, Noncurrent
Other non-current assets
Total other non-current assets
FDA Member.
F D A [Member]
F D A
Summary of reserves for discounts and allowances included in consolidated balance sheets.
Summary Of Reserves For Discounts And Allowances Included In Consolidated Balance Sheets Table [Text Block]
Summary of Total Reserves Included in Consolidated Balance Sheets
Other Accrued Liabilities, Current
Other
Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest
Unrealized gains from available-for-sale securities, net of tax
Interest Paid, Excluding Capitalized Interest, Operating Activities
Cash paid during the period for interest
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Available for sale debt securities, Gross unrealized gains
Available for sale debt securities, Gross unrealized losses
No Individual [Member]
No Individual [Member]
Customer one.
Customer One [Member]
Customer One [Member]
Milestone payment to be paid by company upon specified research milestone achievement.
Milestone Payment To Be Paid By Company Upon Specified Research Milestone Achievement
Contingent research milestone payments
Equity, Attributable to Parent [Abstract]
Stockholders’ equity:
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Earnings Per Share [Abstract]
Development, regulatory and sales milestones payments to be paid
Development Regulatory And Sales Milestone Payments To Be Paid
Development regulatory and sales milestone payments to be paid.
Reduction in the carrying amounts of the right of use assets.
Reduction In The Carrying Amounts Of The Right Of Use Assets
Reduction in the carrying amounts of the right of use assets
PRV
P R V [Member]
P R V
Accounting Policies [Abstract]
Lessee, Lease, Description [Table]
Other Nonoperating Expenses
Other Nonoperating Expenses
Other income (expense), net
Cash and cash equivalents amortized cost basis.
Cash And Cash Equivalents Amortized Cost Basis
Cash and cash equivalents, Amortized cost
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Concentration of Credit Risk
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Other Noncurrent Assets [Member]
Provision for reserves for discounts and allowances.
Provision For Reserves For Discounts And Allowances
Provision
Summary Of Significant Accounting Policies [Table]
Summary Of Significant Accounting Policies [Table]
Summary Of Significant Accounting Policies [Table]
Payments for Rent
Undiscounted rent payment
Development milestone and settlement upfront fee recognized as research and development expense.
Development Milestone And Settlement Upfront Fee Recognized As Research And Development Expense
Development Milestone and Upfront Fee Recognized as Research and Development Expense
Equity Method Investment, Other than Temporary Impairment
Impairment of equity investment
Impairment of equity investment
Impairment of investment in private companies
Remaining lease term
Lessee, Operating Lease, Remaining Lease Term
Net loss per share - basic
Earnings Per Share, Basic, Total
Earnings Per Share, Basic
Cash Equivalents, at Carrying Value
Cash equivalents
Cash Equivalents, at Carrying Value, Total
Schedule of Cash and Cash Equivalents [Table]
Schedule Of Cash And Cash Equivalents [Table]
Customer Concentration Risk [Member]
Customer Concentration Risk [Member]
Commitments and contingencies (Note 16)
Commitments and Contingencies
Income Statement [Abstract]
APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition
Stock-based compensation
Lysogene S.A. [Member]
Lysogene S A [Member]
Lysogene S,A.
Debt Securities, Available-for-Sale, Current
Available for sale debt securities current, Fair value
Debt Securities, Available-for-sale, Current, Total
Payments for (Proceeds from) Tenant Allowance
Tenant improvement allowance
Amount of expenses for award under share-based payment arrangement. Excludes amount capitalized.
Allocated Share Based Compensation Expenses
Stock-based compensation expenses
Operating lease cost
Operating Lease, Cost
2027 Convertible Notes [Member]
Two Thousand And Twenty Seven Senior Convertible Notes [Member]
Two Thousand And Twenty Seven Senior Convertible Notes [Member]
Statistical Measurement [Domain]
Statistical Measurement
Unrealized Gains (losses) on Investments, Net of Tax
Unrealized Gains (losses) on Investments, Net of Tax
Unrealized gains (losses) on investments, net of tax
Net cash used in operating activities
Net Cash Provided by (Used in) Operating Activities
Net cash used in operating activities
Document Period End Date
Document Period End Date
Reduction In Carrying Value Of Convertible Notes
Reduction In Carrying Value Of Convertible Notes
Reduction in carrying value of convertible notes
Statistical Measurement [Axis]
Statistical Measurement
Commitments and Contingencies Disclosure [Text Block]
COMMITMENTS AND CONTINGENCIES
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Notes And Loans Receivable [Line Items]
Net loss per share - diluted
Earnings Per Share, Diluted
Increase in diluted earnings per share (in dollar per share)
Earnings Per Share, Diluted, Total
Henogen SA.
Henogen SA [Member]
Henogen SA [Member]
Concentration Risk Benchmark [Domain]
Contractual Obligation, to be Paid, Year Three
2026
No additional research milestone payments
No Additional Milestone Payment To Be Paid By Company
No additional milestone payment to be paid by company
Debt Instrument, Name [Domain]
Debt Instrument, Name
Fair Value Hierarchy and NAV [Domain]
Fair Value Hierarchy and NAV
Gain (loss) from sale of intangible assets.
Gain Loss From Sale Of Intangible Assets Disclosure [Text Block]
GAIN FROM SALE OF PRIORITY REVIEW VOUCHER
Cost of goods sold excluding amortization.
Cost Of Goods Sold Excluding Amortization
Cost of sales (excluding amortization of in-licensed rights)
Additional Paid in Capital, Common Stock
Additional paid-in capital
Additional Paid in Capital, Common Stock, Beginning Balance
Additional Paid in Capital, Common Stock, Ending Balance
Compound annual growth rate
Compound annual growth rate
Compound annual growth rate of the Company's common stock exceeded that of the Nasdaq.
Schedule of Maturities of Long-Term Debt [Table Text Block]
Summarizes Total Gross Payments Due under Company's Debt Arrangements
Prepaid maintenance services, current.
Prepaid Maintenance Services Current
Prepaid maintenance services
Cash, Cash Equivalents, and Short-Term Investments
Cash, cash equivalents and investments
Cash, Cash Equivalents, and Short-term Investments, Total
2023 (July-December)
Contractual Obligation, to be Paid, Remainder of Fiscal Year
Reserves for reduction to accounts receivable.
Reserves For Reduction To Accounts Receivable
Reduction to accounts receivable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Exercise of options for common stock, shares
Liabilities and Equity [Abstract]
Liabilities and Stockholders’ Equity
Gain from sale of intangible asset.
Gain From Sale Of Intangible Asset [Table]
Gain From Sale Of Intangible Asset [Table]
Restricted stock and restricted stock units.
Restricted Stock And Restricted Stock Units R S Us [Member]
Restricted Stock Awards/Units (RSAs/RSUs) [Member]
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Entity Interactive Data Current
Entity Interactive Data Current
Accounts Receivable Payment Terms
Accounts Receivable Payment Terms
Payment Terms
Revenue, Product and Service [Extensible Enumeration]
Type of Revenue [Extensible List]
2027
Contractual Obligation, to be Paid, Year Five
Grants, Stock options
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Grants, Restricted stock units
Billed Contracts Receivable
Product sales receivable, net of discounts and allowances
Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]
Changes in operating assets and liabilities, net:
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Increase (decrease) in carrying amount of convertible notes.
Increase Decrease In Convertible Notes
Increase in convertible notes
Equity Components [Axis]
Equity Components
Increase (Decrease) in Accounts Receivable
Net increase in accounts receivable
Accrued Income Taxes, Total
Accrued Income Taxes
Accrued income taxes
Strategic Equity Investments [Member]
Strategic Equity Investments [Member]
Inventory Disclosure [Abstract]
Local Phone Number
Local Phone Number
Average closing price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Net decrease in deferred revenue
Increase (Decrease) in Deferred Revenue
Net decrease in deferred revenue
Issuance Of Common Stock For Conversion For Notes Shares
Issuance Of Common Stock For Conversion For Notes Shares
Issuance of common stock for exchange of 2024 Notes, shares
Issuance of common stock for exchange of 2024 Notes, shares
Leasehold improvement receivable current.
Leasehold Improvement Receivable Current
Leasehold improvement receivable
Letter of Credit Reduce
Letter of Credit Reduce
Statement of Cash Flows [Abstract]
Michael A
Director [Member]
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]
FAIR VALUE MEASUREMENTS
Settlement and license charges.
Settlement And License Charges
Settlement and license charges
Settlement charge
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total
Accumulated other comprehensive loss, net of tax
Two Thousand Twenty Four Notes Induced Conversion [Member]
Two Thousand Twenty Four Notes Induced Conversion [Member]
2024 Notes Induced Conversion [Member]
Concentration Risk Benchmark [Axis]
Common Stock, Par or Stated Value Per Share
Common stock, par value
Cash, cash equivalents and investments, Gross unrealized gains
Cash Cash Equivalents And Investments Gross Unrealized Gain Before Tax
Cash cash equivalents and investments gross unrealized gain before tax.
Amount of contractual obligation to be paid after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Contractual Obligation To Be Paid After Year Four
Thereafter
Debt Instrument, Interest Rate, Stated Percentage
Debt instrument, interest rate per annum
Cumulative Effect, Period of Adoption [Axis]
Cumulative Effect, Period of Adoption
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Collaborative Arrangement Disclosure [Text Block]
LICENSE AND COLLABORATION AGREEMENTS
Maximum [Member]
Maximum [Member]
Contractual Obligation, to be Paid, Year One
2024
Prepaid Expense, Noncurrent
Prepaid clinical expenses
Prepaid Expense, Noncurrent, Total
Non-cash interest expense
Noncash Interest Expense
Noncash interest expense.
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
ORGANIZATION AND NATURE OF BUSINESS
Fair Value, Inputs, Level 3 [Member]
Level 3 [Member]
Fair Value, Recurring and Nonrecurring [Table]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Decrease in cash, cash equivalents and restricted cash
Payables and Accruals [Abstract]
First installments
First Installments [Member]
Schedule of Inventory, Current [Table Text Block]
Summary of Components of Inventory
Common stock purchased,shares
Common Stock Purchased
Common stock purchased.
City Area Code
City Area Code
Inventory, Net
Inventory
Total inventory
Inventory
Net Cash Provided by (Used in) Operating Activities [Abstract]
Cash flows from operating activities:
Two thousand and twenty four senior convertible notes.
Two Thousand And Twenty Four Senior Convertible Notes [Member]
2024 Convertible Notes [Member]
Corporate Bonds
Corporate Bonds [Member]
Corporate Bonds [Member]
Customer [Domain]
Selling, General and Administrative Expenses [Member]
Selling, General and Administrative [Member]
Weighted Average Number of Shares Outstanding, Basic
Weighted-average common shares outstanding - basic
Weighted Average Number of Shares Outstanding, Basic, Total
Weighted average number of shares of common stock used in computing basic and diluted net loss per share
Prepaid Taxes
Prepaid income tax
Net Cash Provided by (Used in) Financing Activities [Abstract]
Cash flows from financing activities:
Stock Options Exercised or Expired.
Stock Options Exercised Or Expired
Stock options exercised or expired
Research and development expenses charges.
Research And Development Expenses Charges
Research and development expenses charges
Loss on debt extinguishment
Loss on debt extinguishment
Loss on debt extinguishment
Gain (Loss) on Extinguishment of Debt
Gain (Loss) on Extinguishment of Debt, Total
Statement [Table]
Statement [Table]
Accounts Receivable [Member]
Accounts Receivable [Member]
Document Fiscal Period Focus
Document Fiscal Period Focus
Accrued Professional Fees, Current
Accrued professional fees
Research and Development Expense (Excluding Acquired in Process Cost)
Research and development
Research and Development Expense (Excluding Acquired in Process Cost), Total
Statement [Line Items]
Statement [Line Items]
Schedule of Long-Term Debt Instruments [Table Text Block]
Summary of Debt Facilities
Total fair value of debt facilities
Debt Instrument, Fair Value Disclosure
Debt Instrument Fair Value
Debt Instrument, Fair Value Disclosure, Total
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Anti-dilutive securities excluded from computation of net loss per share
Gain (Loss) on Disposition of Intangible Assets
Gain from sale of Priority Review Voucher
Gain from sale of Priority Review Voucher
Accounts Receivable, after Allowance for Credit Loss, Current
Accounts receivable
Total accounts receivable, net
Cumulative Effect, Period of Adoption [Domain]
Cumulative Effect, Period of Adoption
Customer [Axis]
Common Stock [Member]
Common Stock [Member]
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Lacerta Therapeutics, Inc.
Lacerta Therapeutics Inc [Member]
Lacerta Therapeutics Inc [Member]
Cash and Cash Equivalents, at Carrying Value
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value, Total
Cash and Cash Equivalents, at Carrying Value, Beginning Balance
Cash and Cash Equivalents, at Carrying Value, Ending Balance
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Summary of Stock-Based Compensation Expense by Function Included within Condensed Consolidated Statements of Operations and Comprehensive Loss
Other Assets, Current
Other current assets
Total other current assets
Corporate Bond Securities [Member]
Corporate Bond [Member]
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Cover [Abstract]
Selling, General and Administrative Expense
Selling, general and administrative
Selling, General and Administrative Expense, Total
Commitments and Contingencies [Table]
Commitments And Contingencies [Table]
Commitments And Contingencies [Table]
Long-Term Purchase Commitment, Category of Item Purchased [Domain]
Vesting [Axis]
Document Fiscal Year Focus
Document Fiscal Year Focus
Debt Instrument, Periodic Payment, Principal
Interest Payable, Current
Accrued interest expense
Loss on disposal of assets
Loss on disposal of assets
Gain (Loss) on Disposition of Other Assets
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted Average Grant Date Fair Value, Restricted stock units
2024 Notes Repurchase [Member]
Two Thousand Twenty Four Notes Repurchase [Member]
Two Thousand Twenty Four Notes Repurchase [Member]
Security Exchange Name
Security Exchange Name
Equity investment in a publicly traded security.
Equity Investment Publicly Traded Security
Equity investment publicly traded security
Recognized over approximately the next year
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period
Strategic investments noncurrent.
Strategic Investments Noncurrent
Strategic investments
Schedule of Cash and Cash Equivalents [Table Text Block]
Summary of Company Financial Assets with Maturities of Less Than 90 Days Included in Cash Equivalents
Preferred Stock, Shares Issued
Preferred stock, shares issued
Preferred Stock, Shares Issued, Total
Preferred Stock, Shares Authorized
Preferred stock, shares authorized
Vesting, Stock options
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares
Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]
Summary of Fair Value of Level 3 Financial Assets
Restricted Cash and Investments, Noncurrent
Restricted cash and investments
Restricted Cash and Investments, Noncurrent, Total
Restricted cash
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Lease liabilities arising from obtaining right of use assets
September 20, 2025 [Member]
September Twenty Two Thousand Twenty Five [Member]
September Twenty Two Thousand Twenty Five [Member]
Business Acquisition, Acquiree [Domain]
Business Acquisition, Acquiree
Financial Instrument [Axis]
Financial Instrument
Nationwide Children Hospital.
Nationwide Children Hospital [Member]
NationWide Children Hospital [Member]
Stock Issued During Period, Value, Stock Options Exercised
Exercise of options for common stock
Entity Emerging Growth Company
Entity Emerging Growth Company
Issuance of common stock for exchange of notes shares
Issuance of common stock for exchange of notes shares
Issuance of common stock for exchange of 2024 Notes, shares
Available for sale debt securities current amortized cost basis.
Available For Sale Debt Securities Current Amortized Cost Basis
Available for sale debt securities current, Amortized cost
Amendment Flag
Amendment Flag
Inventory, Noncurrent, Total
Inventory, Noncurrent
Non-current inventory
Other non-current assets
Schedule of Accrued Liabilities [Table Text Block]
Summary of Accrued Expenses
Accrued Marketing Costs, Current
Accrued research costs
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Available for sale debt securities, Gross unrealized losses
Accounting Standards Update [Domain]
Accounting Standards Update
Basis of Accounting, Policy [Policy Text Block]
Basis of Presentation
Category of Item Purchased [Axis]
Employee stock purchase plan.
Employee Stock Purchase Plan [Member]
Employee Stock Purchase Plan [Member]
Prepaid Expense and Other Assets, Noncurrent [Abstract]
Payments to Acquire Debt Securities, Available-for-Sale
Purchase of available-for-sale securities
Leases [Abstract]
Proceeds from sale of rare pediatric disease priority review voucher, Net of commission.
Proceeds From Sale Of Rare Pediatric Disease Priority Review Voucher Net Of Commission
Proceeds from sale of rare pediatric disease priority review voucher, Net of commission
Proceeds From License And Collaborative Agreement.
Proceeds From License And Collaborative Agreement
Proceeds From License And Collaborative Agreement
Securities Act File Number
Entity File Number
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contractual Obligation, to be Paid, Year Two
2025
Goodwill and Intangible Assets Disclosure [Abstract]
Vest of restricted stock units
Restricted Stock Units Vested
Restricted Stock Units Vested
Net (decrease) increase in accounts payable, accrued expenses, lease liabilities and other liabilities
Increase decrease in accounts payable and accrued expenses and other liabilities.
Increase Decrease In Accounts Payable And Accrued Expenses And Other Liabilities
Total cash, cash equivalents and restricted cash
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents
Share-Based Payment Arrangement [Abstract]
Accrued Fixed Assets
Accrued Fixed Assets
Accrued fixed assets
Accounts Payable, Current
Accounts payable
Accounts Payable, Current, Total
Debt Instrument [Axis]
Debt Instrument
Cash, Cash Equivalents, and Marketable Securities [Text Block]
CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES
Payment for full settlement of the principal value and accrued interest
Debt Instrument, Periodic Payment
Debt Instrument, Periodic Payment, Total
Costs and Expenses
Total cost and expenses
Receivables, Net, Current [Abstract]
Long-Term Debt, Maturity, Year One
2024
Accrued product revenue related reserve current.
Accrued Product Revenue Related Reserve Current
Product revenue related reserves
Collaborative Arrangement [Member]
Collaborative Arrangement
Entity Address, Address Line Two
Entity Address, Address Line Two
Preferred Stock, Value, Issued
Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding
Preferred Stock, Value, Issued, Total
Preferred Stock, Value, Issued, Beginning Balance
Preferred Stock, Value, Issued, Ending Balance
Total
Total [Member]
Total [Member]
Entity Small Business
Entity Small Business
Entity Shell Company
Entity Shell Company
Number of Operating Segments
Number of operating segments
Title of Individual [Axis]
Investment Type [Axis]
Investment Type
Share-based payment arrangement, Cost not yet recognized, Amount
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount
Certificates of Deposit [Member]
Certificates of Deposit [Member]
2017 Capped Call Transactions [Member]
Two Thousand Seventeen Capped Call Transactions [Member]
Two Thousand Seventeen Capped Call Transactions [Member]
Earnings Per Share [Text Block]
NET LOSS PER SHARE
Revenues [Abstract]
Revenues:
Commercial Paper [Member]
Commercial Paper [Member]
Entity Address, Address Line One
Entity Address, Address Line One
Revenue Benchmark [Member]
Sales Revenue Net [Member]
Contractual Obligation
Total manufacturing commitments
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Upfront License Fee
Upfront License Fee
Upfront license fee.
Other Liabilities, Current
Other current liabilities
Other Liabilities, Current, Total
Other accruals.
Other Accruals [Member]
Other Accruals [Member]
Other Assets Disclosure [Text Block]
OTHER ASSETS
Accretion of Investment Discount, Net
Accretion of Investment Discount, Net
Accretion of Investment Discount, Net
Income Statement Location [Axis]
Income Statement Location
Long-Term Debt, Maturity, Year Three
2026
Equity Investment Agreement [Member]
Equity Investment Agreement [Member]
Equity investment agreement.
Long-Term Debt, Type [Axis]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net loss
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total
Proceeds from sale of Priority Review Voucher
Proceeds from Sale of Intangible Assets
Prepaid Insurance
Prepaid insurance
Cash cash equivalents and investments gross unrealized loss before tax.
Cash Cash Equivalents And Investments Gross Unrealized Loss Before Tax
Cash, cash equivalents and investments, Gross unrealized losses
Long-Term Purchase Commitment, Amount
Purchase commitment
Fair Value, Inputs, Level 2 [Member]
Level 2 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
Depreciation, Depletion and Amortization
Depreciation and amortization
Depreciation, Depletion and Amortization, Total
Contract with Customer, Liability, Noncurrent
Deferred revenue, net of current portion
Title of 12(b) Security
Title of 12(b) Security
Adjustments To Product Revenue Reserves Relating To Sales In Prior Years
Adjustments To Product Revenue Reserves Relating To Sales In Prior Years
Adjustments relating to prior years
Customer three.
Customer Three [Member]
Customer Three [Member]
Investments [Domain]
Investments
Accounting Standards Update [Axis]
Accounting Standards Update
Net Cash Provided by (Used in) Investing Activities [Abstract]
Cash flows from investing activities:
Amortization of Debt Issuance Costs
Amortization of Debt Issuance Costs
Inventory current and noncurrent net.
Inventory Current and Noncurrent Net
Total inventory
Two Thousand Twenty Seven Notes [Member]
Two Thousand Twenty Seven Notes [Member]
2027 Notes [Member]
Roche.
Roche [Member]
Roche Holding A.G. [Member]
Increase (Decrease) in Inventories
Net increase in inventory
Increase (Decrease) in Inventories, Total
Obligations due to development, regulatory, commercial milestone and up-front royalty payments.
Obligations Due To Development Regulatory Commercial Milestone And Up Front Royalty Payments
Development Milestone and Settlement Upfront Fee Recognized as Research and Development Expense
Contract with Customer, Liability
Deferred Revenue
Contract with Customer, Liability, Total
Accounts Receivable And Reserves For Product Sales [Text Block]
Accounts receivable and reserves for product sales.
PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE AND RESERVES FOR PRODUCT REVENUES
Receivable [Domain]
Receivable
Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award
Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award
Deferred Revenue Separate Material Options Right.
Deferred Revenue Separate Material Options Right
Deferred Revenue Separate Material Options Right
Interest expense debt
Interest Expense, Debt
Interest expense reduced
Interest Expense, Debt, Total
Schedule of Other Nonoperating Income (Expense) [Table Text Block]
Summary of Other Loss
Common stock, shares outstanding
Common Stock, Shares, Outstanding
Common Stock, Shares, Outstanding, Beginning Balance
Common Stock, Shares, Outstanding, Ending Balance
Share-Based Payment Arrangement [Text Block]
STOCK-BASED COMPENSATION
Accrued Royalties, Current
Accrued royalties
Nonrefundable advance
Nonrefundable Advance Payment
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]
Summary of Components of Accounts Receivable
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]
Assets and Liabilities Measured and Carried at Fair Value
Concentration Risk Type [Domain]
Concentration Risk Type
Lease discount rate
Lessee, Operating Lease, Discount Rate
Income Statement Location [Domain]
Income Statement Location
Other investing activity.
Other Investing Activity
Other
Document Type
Document Type
Loans Payable, Noncurrent
Long-term debt
Total carrying value of debt facilities
Accounting Standards Update 2020-06 [Member]
ASU 2020-06
Manufacturing related deposits and prepaid expense non current.
Manufacturing Related Deposits And Prepaid Expense Non Current
Manufacturing-related deposits and prepaids
Prepaid clinical and preclinical expenses current.
Prepaid Clinical And Preclinical Expenses Current
Prepaid clinical and pre-clinical expenses
Net Cash Provided by (Used in) Investing Activities
Net cash provided by (used in) investing activities
Document Quarterly Report
Document Quarterly Report
Nationwide children's hospital.
Nationwide Childrens Hospital [Member]
Nationwide Children?s Hospital [Member]
Counterparty Name [Domain]
Counterparty Name
Manufacturing commitments agreement Member
Manufacturing Commitments Agreement [Member]
Manufacturing Commitments Agreement [Member]
Employee Benefits and Share-Based Compensation
Stock-based compensation Grants
Net Cash Provided by (Used in) Financing Activities
Net cash provided by financing activities
Catalent and Thermo Member
Catalent And Thermo [Member]
Catalent and Thermo [Member]
Debt Instrument, Redemption, Period [Domain]
Short-Term Investments [Member]
Short-term Investments [Member]
Entity Filer Category
Entity Filer Category
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Supplemental schedule of non-cash investing activities and financing activities:
Balance Sheet Location [Domain]
Short-Term Investments
Short-term investments
Short-term Investments, Total
Nonoperating Income (Expense)
Total other (loss), net
Collaboration receivable current.
Collaboration Receivable Current
Collaboration receivable
Liabilities
Total liabilities
Summary Of Significant Accounting Policies [Line Items]
Summary Of Significant Accounting Policies [Line Items]
Summary Of Significant Accounting Policies [Line Items]
Gain on contingent consideration
(Gain) Loss on Contingent Consideration, Net
(Gain) Loss on Contingent Consideration, Net
(Gain) loss on contingent consideration, net
(Gain) loss on contingent consideration, net
Interest Receivable
Interest receivable
Equity, Attributable to Parent
Balance
Balance
Total stockholders’ equity
Carrying value
Intangible Assets, Net (Excluding Goodwill)
Intangible Assets, Net (Excluding Goodwill), Total
Net loss
Nonoperating Income (Expense) [Abstract]
Other loss, net:
Interest Expense
Interest expense
Interest Expense, Total
Issuance of common stock for exchange of notes value
Issuance of common stock for exchange of notes value
Issuance of common stock for exchange of 2024 Notes
Area of Land
Area of lease
Statement of Financial Position [Abstract]
Weighted Average Number of Shares Outstanding, Diluted
Weighted-average common shares outstanding - diluted
Weighted average number of shares of common stock used in computing basic and diluted net loss per share
Other Income and Expenses [Abstract]
Remaining shares associated with performance condition
Remaining Shares Associated With Performance Condition
Remaining Shares Associated With Performance Condition
Debt Securities, Available-for-Sale, Amortized Cost
Available for sale debt securities, Amortized cost
Available for sale debt securities current accumulated gross unrealized gain before tax.
Available For Sale Debt Securities Current Accumulated Gross Unrealized Gain Before Tax
Available for sale debt securities current, Gross unrealized gains
Accrued collaboration cost sharing.
Accrued Collaboration Cost Sharing
Accrued collaboration cost sharing
Bedford Massachusetts
Bedford Massachusetts [Member]
Use of Estimates, Policy [Policy Text Block]
Estimates and Uncertainties
Inducement expense related to debt
Inducement expense related to debt
Inducement expense related to 2024 Notes
Inventory, Work in Process and Raw Materials, Net of Reserves
Work in progress
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Basic and Diluted Net Loss Per Share
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Fair Value Disclosures [Abstract]
Costs and Expenses [Abstract]
Cost and expenses:
Reserves for component of accrued expenses.
Reserves For Component Of Accrued Expenses
Component of accrued expenses
Fair Value Hierarchy and NAV [Axis]
Level 2 [Member]
Fair value convertible note exchange
Fair value convertible note exchange
Fair value convertible note exchange
Payments to Acquire Property, Plant, and Equipment
Purchase of property and equipment
Payments to Acquire Property, Plant, and Equipment, Total
Vesting PSUs
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Employee-related Liabilities, Current
Accrued employee compensation costs
Employee-related Liabilities, Current, Total
Business Acquisition [Axis]
Business Acquisition
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
End of period
Beginning of period
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total
Deferred Revenue, Current
Deferred Revenue, Current
Deferred Revenue, Current, Total
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
Effect of dilutive securities*
Up-front and development milestone expenses.
Up Front And Development Milestone Expenses
Up-front and development milestone expenses